Correspondence 0001193125-23-146106 from BIOCEPT INC (BIOCQ) (CIK 0001044378)
BIOCEPT INC (BIOCQ) (CIK 0001044378)
Date: May 16, 2023 · CIK: 0001044378 · Accession: 0001193125-23-146106
AI Filing Summary & Sentiment
File numbers found in text: 333-271355
Show Raw Text
CORRESP 1 filename1.htm CORRESP Biocept, Inc. 5810 Nancy Ridge Drive San Diego, CA 92121 May 16, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jessica Ansart Re: Biocept, Inc. Registration Statement on Form S-1, as amended (File No. 333-271355) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Biocept, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement on Form S-1 (as amended, the “Registration Statement”) and declare the Registration Statement effective as of 9:00 a.m., Eastern Time, on May 18, 2023, or as soon thereafter as possible, or at such other time as the Company or its counsel may request by telephone to the staff of the Commission. This request for acceleration is subject, however, to your receiving a telephone call prior to such time from Cooley LLP confirming this request. The Company hereby authorizes each of Charles J. Bair and Asa M. Henin of Cooley LLP, counsel to the Company, to make such a request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Asa M. Henin of Cooley LLP at (858) 550-6104, or in his absence, Charles J. Bair of Cooley LLP at (858) 550-6142. Very truly yours, Biocept, Inc. /s/ Samuel D. Riccitelli By: Samuel D. Riccitelli Title: Interim President and Chief Executive Officer